Takeda and Pfizer to Co-Promote Takeda's Actos® for the Treatment of Type 2 Diabetes in China

Pfizer Inc.Takeda Pharmaceutical Company Limited ("Takeda") and Pfizer Inc. ("Pfizer") announced that they have entered into an agreement under which Pfizer in China will co-promote Takeda's Actos® (pioglitazone HCl) with Tianjin Takeda Pharmaceuticals in China. T he exclusive co-promotion agreement will build on the current sales capability for Actos in China by increasing the number of medical representatives supporting the sales and marketing of the product and expanding the product reach utilizing the territory coverage of Pfizer in China, the largest multinational pharmaceutical company in China. Pfizer's Chinese affiliate will receive a fixed ratio of Actos net sales.

Actos, for the treatment of type 2 diabetes, has been sold in China since 2004 by Tianjin Takeda Pharmaceuticals, a joint venture of Takeda Pharmaceutical Company Limited and Tianjin Lisheng Pharmaceutical Co., Ltd., a Chinese company.

Currently the world's fifth largest pharmaceutical market, China is expected to be the third largest market by 2011. According to the International Diabetes Federation, the diabetes epidemic has the greatest potential to increase in China, because of its population size, rapid urbanization and economic expansion.

"Takeda has a significant opportunity to increase our presence in China, and we are pleased to be partnering with Pfizer to make Actos even more widely available to patients in China," said Alan MacKenzie, executive vice president, international operations, Takeda Pharmaceuticals International, Inc. "We are committed to contributing to the health of people in China through a strong sales and marketing framework that provides enhanced access to our products for patients and healthcare providers, and we look forward to further expanding our talent base in China to realize this goal."

"The combination of Takeda's industry leading product, backed by compelling clinical evidence and Pfizer"s strong capability and coverage in China creates a winning partnership," said Ian Read, senior vice president and group president, Pfizer Worldwide Biopharmaceutical Businesses. "According to the International Diabetes Federation, China is estimated to have more than 50 million diabetics by 2025, and we are delighted to partner with Takeda to provide these people with the opportunity to live healthier lives. Pfizer is committed to helping the Chinese Government address its top public health priorities in an innovative, socially responsible and commercially viable manner."

About Takeda Pharmaceutical Company Limited
Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate Web site, www.takeda.com.

About Pfizer Inc.: Working together for a healthier world™
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizer.com.

Most Popular Now

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

More stroke patients may receive crucial treatment…

More patients could be eligible for critical treatments to remove or dissolve blood clots that cause strokes, according to a new treatment guideline issued by the America...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Guidelines extended to improve the use of feedback…

Researchers have recommended changes to international guidelines used in the development of clinical trials in an effort to gain information about the impact of the treat...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

Brilinta significantly reduces CV events and coron…

AstraZeneca today announced results from a new sub-analysis of the Phase III PEGASUS-TIMI 54 trial, demonstrating a risk reduction of 19% in MACE (the composite of CV dea...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]